title: Pelvic exenteration for recurrent endometrial adenocarcinoma: a retrospective multi-institutional study about 21 patients.
abstract: OBJECTIVE
  The aim of our study was to evaluate morbidity, mortality, and long-term survival of patients who underwent pelvic exenteration (PE) with curative intent for recurrence of endometrial adenocarcinoma during a single decade.
  
  
  METHODS
  We defined a cohort of 21 patients who met our inclusion criteria, referred to 4 cooperating gynecologic oncology settings in Germany and Italy between 2000 and 2011. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until the last follow-up or death.
  
  
  RESULTS
  The median age was 66 years. A total of 42.9% of the patients had major complications, and a complete resection was achieved in 85.7% of the patients. A total of 71.4% of the patients had negative nodes. No patient died intraoperatively. The perioperative mortality, calculated within 30 days from PE, was 4.8%. The overall 5-year survival rate, evaluated using the Kaplan-Meier method, was 40%. For the subgroup with complete resection and negative lymph nodes, overall survival reached 60%.
  
  
  CONCLUSIONS
  Despite a high complication rate, PE for solitary pelvic recurrence of endometrial cancer yields a high rate of long-term survival.
authors.affiliation: *Department of Gynecology and Gynecological Oncology, Campus Mitte (CCM) and Campus Benjamin Franklin (CBF), Charitè University, Berlin, Germany; †Gynecologic Oncology Unit, S. Orsola-Malpighi Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy; ‡Department of Radiooncology, Campus Mitte (CCM) and Campus Virchow (CVK), Charitè University, Berlin, Germany; §Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy; ∥Università di Milano, Fondazione Policlinico, Milan, Italy; and ¶Gynecologic Oncology Unit, Catholic University of the Sacred Heart, Campobasso, Italy.
authors.forename: Vito
authors.initials: V
authors.lastname: Chiantera
authors.forename: Martina
authors.initials: M
authors.lastname: Rossi
authors.forename: Pierandrea
authors.initials: P
authors.lastname: De Iaco
authors.forename: Christardt
authors.initials: C
authors.lastname: Koehler
authors.forename: Simone
authors.initials: S
authors.lastname: Marnitz
authors.forename: Valerio
authors.initials: V
authors.lastname: Gallotta
authors.forename: Alessandro Pasquale
authors.initials: AP
authors.lastname: Margariti
authors.forename: Fabio
authors.initials: F
authors.lastname: Parazzini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Achim
authors.initials: A
authors.lastname: Schneider
authors.forename: Giuseppe Filiberto
authors.initials: GF
authors.lastname: Vercellino
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000368:Aged; D000369:Aged, 80 and over; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D010385:Pelvic Exenteration; D010386:Pelvic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate